Ari­ad’s briga­tinib scores 15.6 month PFS rate; Neurim­mune backs ALS spin­out

Ari­ad Phar­ma­ceu­ti­cals is re­port­ing that its ALK in­hibitor briga­tinib scored a 55% ob­jec­tive re­sponse rate in among pa­tients tak­ing 180 mg. In this same arm the PFS rate was a me­di­an 15.6 months. “These up­dat­ed AL­TA tri­al da­ta show that with ad­di­tion­al fol­low-up, me­di­an pro­gres­sion-free sur­vival from briga­tinib giv­en post-crizo­tinib is now 15.6 months, and that this is the same whether as­sessed by the in­ves­ti­ga­tors or an in­de­pen­dent re­view com­mit­tee,” said D. Ross Camidge, MD, PhD., di­rec­tor of tho­racic on­col­o­gy at the Uni­ver­si­ty of Col­orado.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER